Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment.
Laura LambrechtPaola ArnoldJuergen BehrPontus MertschAmanda TufmanDiego Kauffmann-GuerreroPublished in: Diagnostics (Basel, Switzerland) (2024)
The efficacy of topotecan in SCLC real-world patients is poor, indicating that many patients were treated without any benefit. Easy-to-obtain markers can predict response and treatment efficacy and should therefore be validated in larger cohorts to identify patients who are more likely to benefit from topotecan.